Results 241 to 250 of about 457,473 (371)

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2. [PDF]

Viruses, 2020
Wang J, Prinz RA, Liu X, Xu X.
europepmc   +1 more source

Additional file 2: Figure S1. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

, 2016
Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, Hirotoshi Yuasa, Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose, Samuel H. Zwillich   +8 more
openalex   +1 more source

Supplementary Movie 1 from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1

, 2023
Jeanette Nilsson, Khalil Helou, Anikó Kovács, Pär‐Ola Bendahl, Gunnar Bjursell, Mårten Fernö, Peter Carlsson, Marie Kannius‐Janson   +7 more
openalex   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway. [PDF]

Bioengineered, 2021
Danni X, Jiangzheng Z, Huamao S, Yinglian P, Changcheng Y, Yanda L.   +5 more
europepmc   +1 more source

Beyond cell-cell adhesion: Emerging roles of the tight junction scaffold ZO-2 [PDF]

, 2013
Gehwolf, R., Krizbai, István Adorján, Toepfer, S., Traweger, A., Wagner, R.N., Wilhelm, Imola, Zweimueller-Mayer, J.   +6 more
core   +1 more source

The Effect of Empagliflozin on Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway in Patients with Type 2 Cardiorenal Syndrome. [PDF]

Anatol J Cardiol
Zhou P, Tang X, Deng Y, Wu R, Yi Y, Deng H, Cao Q.   +6 more
europepmc   +1 more source

Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis [PDF]

, 2019
Yves Allenbach, L. Bolko, S. Toquet, Océane Landon‐Cardinal, Olivier Benveniste   +4 more
openalex   +1 more source

Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells.

Molecular Medicine Reports, 2016
Weijie Cao, Ke-Wei Wu, Chong Wang, D. Wan   +3 more
semanticscholar   +1 more source